Celldex Therapeutics (CLDX +1.5%) gets a boost after announcing positive results in its Phase 2...


Celldex Therapeutics (CLDX +1.5%) gets a boost after announcing positive results in its Phase 2 clinical trials for rindopepimut, a drug treatment for brain cancer patients with newly diagnosed glioblastoma.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs